AI Terminal
Indivior PLC
Investor Presentation • Nov 1, 2022
4923_rns_2022-11-01_da27f695-34aa-4a87-a690-dba4af8d6bb4.html
Investor Presentation
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 8845E
Indivior PLC
01 November 2022
Indivior To Participate In Upcoming Stifel 2022 Healthcare Conference
Slough, UK, and Richmond, VA, November 1, 2022 - Indivior PLC (LON: INDV) today announced that Mark Crossley, Chief Executive Officer, and Ryan Preblick, Chief Financial Officer, will participate in the Stifel 2022 Healthcare Conference in New York City. Mr. Crossley will participate in a fireside chat to be held on Tuesday, November 15th at 9:10 AM US EST (14:10 London time). The live fireside chat can be accessed using the following weblink: Stifel Healthcare Conference (wsw.com)
About Indivior
Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat substance use disorders (SUD) and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder. Headquartered in the United States in Richmond, VA, Indivior employs approximately 1,000 individuals globally and its portfolio of products is available in over 40 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior.
Contact:
Jason Thompson
Vice President, Investor Relations
Tel: 804-402-7123 or [email protected]
Tim Owens
Director, Investor Relations
Tel: 804-263-3978 or [email protected]
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
MSCEANFFEEXAFEA